The week's thread — 4 October 2026

Twenty-five rounds with disclosed amounts totalling roughly €181 million crossed the wire this week, from Monday 28 September to Thursday 2 October, across fourteen countries. The number flatters the picture: two rounds alone — Aptadir Therapeutics (Milan, €40M Seed) and Kasvu Therapeutics (Helsinki, €30M Series A) — account for €70 million, or 39% of the week's total. Strip them out and the week is a steady, unremarkable stream of early-stage software and AI rounds. The week's genuine shape is more interesting than either number alone.

The biotech outliers

Aptadir Therapeutics raised the week's largest round: a €40M Seed for a preclinical RNA platform targeting rare genetic diseases, led by 4BIO Capital alongside CDP Venture Capital, XGEN Venture, and CE-Ventures. The company's directional RNA inhibitor mechanism claims a distinct niche from the more mapped siRNA and antisense oligonucleotide landscape; the fragile X syndrome indication is the right first test for a platform bet, but clinical proof is measured in years. At €40M, the round is pricing platform rarity, not near-term revenue.

Kasvu Therapeutics (Helsinki) closed a €30M Series A led by Hadean Ventures for KTX-0141, a TrkB positive allosteric modulator targeting major depressive disorder without psilocybin's supervised-session requirement. Clinical start is targeted for H2 2027. Two Finnish universities and three institutional life science funds participated alongside Hadean. Neither Aptadir nor Kasvu fits the dominant "AI startup" narrative of the past several weeks; both are patient bets on biological mechanisms where capital requirements are large and development timelines are set by biology, not by product iteration speed.

France led the count; enterprise AI continued to fill in

Eight of the week's twenty-five rounds came from France — 32% by count, roughly 21% by capital. The range was wide. Mallow raised €11M (Balderton Capital, Daphni, Motier Ventures) for a screen-free AI audio speaker for children built on a Mistral AI stack, co-founded by Cédric O. Rayon closed a €10M Series A led by Partech for its browser-native CAD and project management platform for interior designers, with Norman Foster and the founder of ArchDaily among the angel investors. Marble raised €6.5M Series A (Smartfin) for an open-source FRAML compliance platform now protecting 3 billion+ transactions annually at 100+ institutions across 25 countries. At the smaller end, C-Clerc (€1.2M, notarial AI on sovereign infrastructure) and Iopole (€3M, e-invoicing platform) both built businesses around regulatory mandates rather than discretionary demand — a structural distribution advantage that concentrates near-term pipeline but depends on sustained retention after deadlines pass.

Germany contributed two rounds that bridged the same week's AI-for-enterprise strand to something more structural: Restate (Berlin, €18.5M Series A, Singular) builds durable execution infrastructure that makes AI agents and distributed workflows resilient across failures — a layer beneath the deployment rounds, not above them. Ahron (Munich, €2.2M, Cusp Capital) deploys AI agents into enterprise HR systems with centralized governance guardrails. Sweden contributed the week's most credible industrial AI story: IPercept (Stockholm, €14.7M Series A, Isogon Ventures and 2150), a KTH spinout with Airbus, Bosch, and Volvo as customers for its CNC machine health sensor. The customer base is the signal.

What the week shows

The week's capital split roughly 39/61 between two patient, biology-constrained bets and everything else. The "everything else" was mostly software companies at sub-€20M deploying AI into specific professional domains — a pattern that has held across the past four weeks of ProYarn coverage. What shifted this week was the scale of the outliers at the top. A €40M Seed for a preclinical biotech is unusual anywhere in Europe; two large life-science seeds — Aptadir and Kasvu — in the same brief window suggests the European deep-tech investor base is deploying again after a quieter mid-year. Whether that's a trend or two coincident announcements will become legible over the next month.

Thursday's cluster — seven rounds across six countries — was the week's most active single brief. Wednesday's nine rounds were close. Friday and the weekend produced nothing. The rhythm is familiar.